相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma
L. Albiges et al.
ANNALS OF ONCOLOGY (2021)
The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care
Jens Bedke et al.
EUROPEAN UROLOGY (2021)
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Immune Checkpoint Inhibitors in Metastatic Clear-cell Renal Cell Carcinoma: Is PD-L1 Expression Useful?
Laurence Albiges et al.
EUROPEAN UROLOGY (2021)
Nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in pretreated patients (pts) with metastatic renal cell carcinoma (mRCC): First results of phase II NIVES study.
Cristina Masini et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC).
Hans J. Hammers et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
T.K. Choueiri et al.
ANNALS OF ONCOLOGY (2020)
BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer
Nicolas Epaillard et al.
BULLETIN DU CANCER (2020)
Cytoreductive Nephrectomy in Metastatic Patients with Signs or Symptoms: Implications for Renal Cell Carcinoma Guidelines
Alessandro Larcher et al.
EUROPEAN UROLOGY (2020)
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
Thomas Powles et al.
LANCET ONCOLOGY (2020)
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
Laurence Albiges et al.
ESMO OPEN (2020)
Stereotactic Radiation Therapy for Renal Cell Carcinoma Brain Metastases in the Tyrosine Kinase Inhibitors Era: Outcomes of 120 Patients
Guillaume Klausner et al.
CLINICAL GENITOURINARY CANCER (2019)
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update
Borje Ljungberg et al.
EUROPEAN UROLOGY (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on Carmena trial with focus on intermediate IMDC-risk population.
Arnaud Mejean et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).
Leonard Joseph Appleman et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Brian I. Rini et al.
LANCET (2019)
Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019
Marc-Oliver Grimm et al.
EUROPEAN UROLOGY (2019)
Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma
Bimal Bhindi et al.
EUROPEAN UROLOGY (2019)
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib The SURTIME Randomized Clinical Trial
Axel Bex et al.
JAMA ONCOLOGY (2019)
Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies
Nicholas G. Zaorsky et al.
EUROPEAN UROLOGY ONCOLOGY (2019)
Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study
Giuseppe Procopio et al.
EUROPEAN UROLOGY ONCOLOGY (2019)
Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review
Idir Ouzaid et al.
EUROPEAN UROLOGY ONCOLOGY (2019)
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma
A. Mejean et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cytoreductive Nephrectomy — Patient Selection Is Key
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Daniel Y. C. Heng et al.
EUROPEAN UROLOGY (2014)
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update
Cora N. Sternberg et al.
EUROPEAN JOURNAL OF CANCER (2013)
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The efficacy of external beam radiotherapy and stereotactic body radiotherapy for painful spinal metastases from renal cell carcinoma
Grant K. Hunter et al.
PRACTICAL RADIATION ONCOLOGY (2012)
Survival After Complete Surgical Resection of Multiple Metastases From Renal Cell Carcinoma
Angela L. Alt et al.
CANCER (2011)
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study
Daniel Y. C. Heng et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis
RC Flanigan et al.
JOURNAL OF UROLOGY (2004)
分享论文
